Tafamidis Meglumine

氯苯唑酸葡甲胺

Report date: 2026/04/08 20:02:35
NMEFirst In Class

Base Information

Drug NameTafamidis Meglumine
Drug Alias NameTafamidis meglumine维达全VyndaqelPF-6291826Fx-1006A +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransthyretin stabilizers
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisAmyloidosisCardiomyopathies +[6] 
Global Approved IndicationsTransthyretin amyloidosisAmyloidosisCardiomyopathies +[4] 
Approved Indications in ChinaAmyloid Neuropathies
Original Approved Country/TerritoryEU
Original Approved Date2011/11/16
Country/TerritoryCzechiaBelgiumCanada +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Japan IncPfizer Europe Ma Eeig
Inactive CompaniesFoldrx Pharmaceuticals Inc
Active IndicationsTransthyretin amyloidosisAmyloidosisCardiomyopathies +[4] 
Inactive IndicationsAmyloid Neuropathies, FamilialImmunoglobulin Light-chain Amyloidosis

Other Information

ATC CodeN07XX08
Related LinksWikipediaDrugBankKEGG